| 產(chǎn)品編號(hào) | BIO1018SM |
| 英文名稱 | Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab Biosimilar) |
| 別 名 | Angiopoietin 2 & VEGF; Reozalimab |
| 抗體來(lái)源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 143.84kDa |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Reozalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Reozalimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.728 nM.
Reozalimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-L1-CHO-K cells, and the EC50 was 2.237 nM.
Reozalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-1-Jurkat cells, and the EC50 was 0.990 nM.
Reozalimab bound to PD-L1 protein, and then rebounded to secondary antibodies(Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-L1-Fc, and the EC50 was 0.015 nM.
Reozalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-1-His, and the EC50 was 0.004 nM.
The purity of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 95.07%, determined by SEC-HPLC.
Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected weight of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 143.56 kDa.
|
